Clinical Trials for Curing Chronic Hepatitis B: A Comprehensive Analysis of Trial Design Considerations and Their Association With Trial Performance
Smaller and shorter early-phase trials were more likely to complete, whereas novel trial designs were not associated with faster completion. Direct-acting antivirals showed marked end-of-treatment HBsAg decline, an on-treatment signal rather than durable functional cure.
Authors
- Yuanyuan Kong (ORCID: https://orcid.org/0000-0002-1282-3536)
- Hao Wang (ORCID: https://orcid.org/0000-0001-6881-9977)
- Jidong Jia
- Lichen Shi
- Cheng Huang
- Hong You
- Yifan Du
Institutions
- Capital Medical University (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Institut de Recherche en Santé Digestive (FR)
- Beijing Friendship Hospital (CN)
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1111/jgh.70346
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00